Complete all fields below to register to view protected pages of this site.
Remplissez les champs d’inscription ci-dessous afin de visualiser les pages protégées de ce site.
Vervollständigen Sie alle untenstehenden Felder um sich zu registrieren und die geschützten Bereiche dieser Internetseite einzusehen.
Completa tutti i campi sottostanti per poter accedere alle pagine protette di questo sito.
Por favor, complete sus datos personales a continuación. Toda la información es necesaria.
SAN DIEGO, March 15, 2015 – Edwards Lifesciences Corporation (NYSE: EW), the global leader in the science of heart valves and hemodynamic monitoring, today announced that 30-day outcomes for high- and intermediate-risk patients treated with the SAPIEN 3 transcatheter aortic valve demonstrated the lowest all-cause mortality rates of any of the PARTNER studies, as well as excellent clinical outcomes on the other components of the primary endpoint measures of stroke and paravalvular regurgitation.